Monitor Q4 2026 for first product revenue recognition and early prescription trends; the sNDA decision for the PIK3CA mutant cohort and VIKTORIA-2 enrollment updates are key catalysts. Cash runway through 2029 removes near-term financing risk.
Drug in focus
CELC drug pipeline →REVTORPYK
◆ Mixed Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Next catalyst
- None dated
What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $66.79entry
- T+1 · 8d ago +5.36%α +2.99% · $70.37
- T+5 · 4d ago −3.62%α −6.22% · $64.37
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Celcuity reported Q3 2026 GAAP net loss of $1.33 per share, wider than the $1.53 consensus estimate (a beat), and no product revenue as REVTORPYK shipments began on September 30 but product was not received by customers until after quarter-end. The company highlighted a strong early launch with 78% of top strategic accounts ordering REVTORPYK and 91% commercial/Medicare coverage, while cash runway extends through 2029.
Key Financial Metrics
Key Facts
- GAAP net loss $73.3M ($1.33/share) vs $43.8M ($0.92/share) year ago
- Non-GAAP adjusted net loss $66.8M ($1.21/share) vs $37.2M ($0.78/share) year ago
- No product revenue recognized in Q3; first REVTORPYK shipments began Sep 30
- Total operating expenses $77.3M, up from $42.8M, driven by commercial buildout
- Cash, equivalents and investments $642.7M; expected to fund operations through 2029
- 91% of U.S. commercial and Medicare lives covered for REVTORPYK
- 78% of top 36 strategic accounts have ordered REVTORPYK
- sNDA for PIK3CA mutant cohort submitted to FDA in Q3 2026
- VIKTORIA-2 Phase 3 trial enrollment ongoing in first-line HR+/HER2- ABC
Financial Impact
Net loss widened by $29.5M YoY; operating expenses nearly doubled to $77.3M due to commercial launch costs; cash burn $66.2M in operating activities plus $50M milestone payment to Pfizer
Risk Factors
- No product revenue yet; commercial ramp may be slower than expected
- sNDA for PIK3CA mutant cohort faces FDA review risk
- Competition from alpelisib and other PI3K/AKT/mTOR inhibitors
- High cash burn rate ($66.2M operating cash flow in Q3) may accelerate if launch costs persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396999 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers